These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

285 related articles for article (PubMed ID: 27858176)

  • 1. Serum level of reactive oxygen metabolites (ROM) at 12 weeks of treatment with biologic agents for rheumatoid arthritis is a novel predictor for 52-week remission.
    Nakajima A; Aoki Y; Sonobe M; Takahashi H; Saito M; Nakagawa K
    Clin Rheumatol; 2017 Feb; 36(2):309-315. PubMed ID: 27858176
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Identification of clinical parameters associated with serum oxidative stress in patients with rheumatoid arthritis.
    Nakajima A; Aoki Y; Shibata Y; Sonobe M; Terajima F; Takahashi H; Saito M; Taniguchi S; Yamada M; Nakagawa K
    Mod Rheumatol; 2014 Nov; 24(6):926-30. PubMed ID: 24670128
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Biomarkers in Remission According to Different Criteria in Patients with Rheumatoid Arthritis.
    Yilmaz-Oner S; Ozen G; Can M; Atagunduz P; Direskeneli H; Inanc N
    J Rheumatol; 2015 Nov; 42(11):2066-70. PubMed ID: 26472417
    [TBL] [Abstract][Full Text] [Related]  

  • 4. High rate of improvement in serum matrix metalloproteinase-3 levels at 4 weeks predicts remission at 52 weeks in RA patients treated with adalimumab.
    Hattori Y; Kojima T; Kaneko A; Kida D; Hirano Y; Fujibayashi T; Yabe Y; Oguchi T; Kanayama Y; Miyake H; Kato T; Takagi H; Hayashi M; Ito T; Shioura T; Takahashi N; Ishikawa H; Funahashi K; Ishiguro N
    Mod Rheumatol; 2018 Jan; 28(1):119-125. PubMed ID: 28463029
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Serum levels of reactive oxygen metabolites at 12 weeks during tocilizumab therapy are predictive of 52 weeks-disease activity score-remission in patients with rheumatoid arthritis.
    Nakajima A; Terayama K; Sonobe M; Aoki Y; Takahashi H; Akatsu Y; Saito J; Taniguchi S; Yamada M; Kubota A; Nakagawa K
    BMC Rheumatol; 2019; 3():48. PubMed ID: 31891116
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The efficacy of abatacept in Japanese patients with rheumatoid arthritis: 104 weeks radiographic and clinical results in clinical practice.
    Mochizuki T; Yano K; Ikari K; Hiroshima R; Takaoka H; Kawakami K; Koenuma N; Shirahata T; Momohara S
    Mod Rheumatol; 2016 Jul; 26(4):499-506. PubMed ID: 26473281
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Normal serum matrix metalloproteinase-3 levels can be used to predict clinical remission and normal physical function in patients with rheumatoid arthritis.
    Hattori Y; Kida D; Kaneko A
    Clin Rheumatol; 2019 Jan; 38(1):181-187. PubMed ID: 28940139
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Infliximab equivalently suppresses oxidative stress compared to tocilizumab among well-controlled patients with rheumatoid arthritis.
    Kizaki K; Yamashita F; Hayashi T; Funakoshi N
    Int J Rheum Dis; 2018 Oct; 21(10):1815-1821. PubMed ID: 27778459
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Physician global assessment at 3 months is strongly predictive of remission at 12 months in early rheumatoid arthritis: results from the CATCH cohort.
    Choy T; Bykerk VP; Boire G; Haraoui BP; Hitchon C; Thorne C; Keystone EC; Pope JE;
    Rheumatology (Oxford); 2014 Mar; 53(3):482-90. PubMed ID: 24241035
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Thresholds for the 28-joint disease activity score (DAS28) using C-reactive protein are lower compared to DAS28 using erythrocyte sedimentation rate in early rheumatoid arthritis.
    Kuriya B; Schieir O; Lin D; Xiong J; Pope J; Boire G; Haraoui B; Thorne JC; Tin D; Hitchon C; Jamal S; Keystone E; Bykerk VP;
    Clin Exp Rheumatol; 2017; 35(5):799-803. PubMed ID: 28339365
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Longitudinal study of clinical prognostic factors in patients with early rheumatoid arthritis: the PREDICT study.
    Bird P; Nicholls D; Barrett R; de Jager J; Griffiths H; Roberts L; Tymms K; McCloud P; Littlejohn G;
    Int J Rheum Dis; 2017 Apr; 20(4):460-468. PubMed ID: 28205333
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Baseline Serum Osteopontin Levels Predict the Clinical Effectiveness of Tocilizumab but Not Infliximab in Biologic-Naïve Patients with Rheumatoid Arthritis: A Single-Center Prospective Study at 1 Year (the Keio First-Bio Cohort Study).
    Izumi K; Kaneko Y; Hashizume M; Yoshimoto K; Takeuchi T
    PLoS One; 2015; 10(12):e0145468. PubMed ID: 26698858
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The comparative responsiveness of the patient self-report questionnaires and composite disease indices for assessing rheumatoid arthritis activity in routine care.
    Salaffi F; Ciapetti A; Gasparini S; Carotti M; Bombardieri S;
    Clin Exp Rheumatol; 2012; 30(6):912-21. PubMed ID: 22935335
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Decrement of serum cartilage oligomeric matrix protein (COMP) in rheumatoid arthritis (RA) patients achieving remission after 6 months of etanercept treatment: comparison with CRP, IgM-RF, MMP-3 and anti-CCP Ab.
    Kawashiri SY; Kawakami A; Ueki Y; Imazato T; Iwamoto N; Fujikawa K; Aramaki T; Tamai M; Nakamura H; Origuchi T; Ida H; Eguchi K
    Joint Bone Spine; 2010 Oct; 77(5):418-20. PubMed ID: 20864374
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Serum Reactive Oxygen Metabolites as a Predictor of Clinical Disease Activity Index, Simplified Disease Activity Index, and Boolean Remissions in Rheumatoid Arthritis Patients Treated With Biologic Agents.
    Nakajima A; Terayama K; Sonobe M; Akatsu Y; Saito J; Norimoto M; Taniguchi S; Kubota A; Aoki Y; Nakagawa K
    Cureus; 2021 Nov; 13(11):e19759. PubMed ID: 34938634
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Efficacy and safety of golimumab in Indian patients with rheumatoid arthritis: Subgroup data from GO-MORE study.
    Pal S; Veeravalli SC; Das SK; Shobha V; Uppuluri RR; Dharmanand BG; Nadkar M; Hsia E; Fei K; Yao R; Khalifa A
    Int J Rheum Dis; 2016 Nov; 19(11):1083-1092. PubMed ID: 27457311
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Characteristics of patients with rheumatoid arthritis in Qatar: a cross-sectional study.
    Lutf A; Poil AR; Hammoudeh M
    Int J Rheum Dis; 2014 Jan; 17(1):63-5. PubMed ID: 24472269
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Monitoring C-reactive protein levels to predict favourable clinical outcomes from tocilizumab treatment in patients with rheumatoid arthritis.
    Kojima T; Yabe Y; Kaneko A; Hirano Y; Ishikawa H; Hayashi M; Miyake H; Takagi H; Kato T; Terabe K; Wanatabe T; Tsuchiya H; Kida D; Shioura T; Funahashi K; Kato D; Matsubara H; Takahashi N; Hattori Y; Asai N; Ishiguro N
    Mod Rheumatol; 2013 Sep; 23(5):977-85. PubMed ID: 23099471
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Comparison of the DAS28-CRP and DAS28-ESR in patients with rheumatoid arthritis.
    Sengul I; Akcay-Yalbuzdag S; Ince B; Goksel-Karatepe A; Kaya T
    Int J Rheum Dis; 2015 Jul; 18(6):640-5. PubMed ID: 26013310
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Serum Calprotectin Versus Acute-Phase Reactants in the Discrimination of Inflammatory Disease Activity in Rheumatoid Arthritis Patients Receiving Tumor Necrosis Factor Inhibitors.
    Inciarte-Mundo J; Victoria Hernández M; Ruiz-Esquide V; Raquel Cabrera-Villalba S; Ramirez J; Cuervo A; Pascal M; Yagüe J; Cañete JD; Sanmarti R
    Arthritis Care Res (Hoboken); 2016 Jul; 68(7):899-906. PubMed ID: 26841119
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.